Nyxoah gains FDA approval for its Genio system, signaling a major growth milestone. Explore revenue growth, risks, and why ...

Q2 2025 Earnings Call Transcript August 18, 2025 Nyxoah S.A. misses on earnings expectations. Reported EPS is $-0.63 EPS, ...

Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in ...

Nyxoah ( ($NYXH) ) has provided an update. On August 18, 2025, Nyxoah SA announced its financial and operating results for the second quarter and ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

We raise our fair value estimate for wide-moat Cochlear by 2% with the time value of money. Shares are overvalued as the ...

Our healthcare analyst Shane Ponraj helps me compare the moatiness and growth prospects of two sector heavyweights.

The RealReal (Nasdaq: REAL)-the world’s largest online marketplace for authenticated, resale luxury goods-announced today ...